EU MDR Classification Rules: All 22 Rules with Examples and Decision Tree

Understanding EU MDR Classification: The Foundation of Market Access

The European Union Medical Device Regulation (EU MDR 2017/745) replaced the Medical Device Directive (MDD) and fundamentally changed how medical devices are classified for the European market. Classification under EU MDR is not an administrative exercise — it determines which conformity assessment pathway your device must follow, which Notified Body involvement is required, and critically for this discussion, which tender requirements apply to your products. Getting classification wrong does not just delay market access. It means your tender responses cite the wrong conformity assessment evidence, leading to disqualification from procurement processes.

EU MDR Annex VIII contains 22 classification rules organized into four groups based on device type. Understanding these rules — and the common mistakes manufacturers make when applying them — is essential for any medical device company competing in European tenders.

Group 1: Non-Invasive Devices (Rules 1-4)

Rule 1 covers non-invasive devices that do not touch the patient or contact only intact skin. These are generally Class I. Examples include hospital beds, examination gloves, and stethoscopes. Most do not require Notified Body involvement for conformity assessment, though they must still meet general safety and performance requirements.

Rule 2 addresses channeling or storing devices — those that channel blood, body fluids, or tissues. Blood bags and tubing sets fall here. If intended for storage, they may be Class IIa or IIb depending on modification risk.

Rule 3 covers non-invasive devices that modify the biological or chemical composition of blood, other body fluids, or liquids intended for infusion. Dialysis concentrates and blood filters are classified under this rule, typically as Class IIb.

Rule 4 applies to non-invasive devices that contact injured skin. Wound dressings are the primary example. Classification ranges from Class I for conventional dressings to Class IIb for dressings intended for chronic wounds or that incorporate biological active agents.

Group 2: Invasive Devices (Rules 5-8)

Rule 5 covers invasive devices related to body orifices (non-surgical). Short-term use devices like examination mirrors are Class I. Devices for continuous or repeated use over longer periods, such as urinary catheters, are Class IIa or IIb.

Rule 6 addresses surgically invasive devices for transient use — those intended to be used continuously for less than 60 minutes. Surgical suture needles and single-use scalpels fall here. Most are Class IIa unless they involve the central nervous system or heart, which elevates them to Class III.

Rule 7 covers surgically invasive devices for short-term use (up to 30 days of continuous use). Surgical drains and temporary pacing electrodes are examples. Again, devices that contact the heart or central nervous system are elevated to Class III.

Rule 8 applies to implantable devices and long-term surgically invasive devices — those intended to remain in the body for more than 30 days. Joint prostheses, cardiac stents, and cochlear implants are classified under this rule, typically as Class IIb or Class III. All implantable devices that contact the heart or central circulatory system are Class III.

Group 3: Active Devices (Rules 9-13)

Rule 9 covers active therapeutic devices intended to deliver or exchange energy. Surgical lasers, radiotherapy equipment, and powered surgical instruments fall here. Most are Class IIa unless they deliver energy in a potentially hazardous way, which elevates them to Class IIb.

Rule 10 addresses active diagnostic devices. Patient monitors, diagnostic ultrasound systems, and imaging equipment are classified under this rule. Devices that provide images or data used for direct patient management decisions are typically Class IIa. Those supplying energy absorbed by the patient for diagnostic purposes (like X-ray systems) are Class IIb.

Rule 11 applies to software. This is one of the most significant changes under EU MDR compared to the previous directive. Software intended to provide information used for diagnosis or therapy decisions is classified based on the potential impact of those decisions. Software that drives or influences Class III device decisions is itself Class III. Standalone diagnostic software can be Class IIa, IIb, or III depending on the clinical situation it addresses.

Rule 12 covers active devices that administer or remove medicinal products, body fluids, or other substances. Infusion pumps and anesthesia machines are primary examples, typically classified as Class IIa or IIb.

Rule 13 assigns all other active devices not covered by Rules 9-12 to Class I. This is a residual rule for active devices that have minimal risk profiles.

Group 4: Special Rules (Rules 14-22)

Rules 14 through 22 address specific device types that require special classification consideration. Rule 14 covers devices incorporating a medicinal substance (Class III). Rule 15 addresses contraceptive and sexually transmitted disease prevention devices. Rule 16 covers disinfection and sterilization devices. Rule 17 applies to devices for recording diagnostic images (X-ray film). Rule 18 covers devices utilizing non-viable animal tissues. Rule 19 addresses devices incorporating nanomaterials (elevated by one class). Rule 20 covers invasive devices for body orifices used for administration of inhaled medicinal products. Rule 21 addresses devices composed of substances introduced into the body. Rule 22 covers active therapeutic devices with integrated diagnostic functions — a growing category as combination products become more common.

Common Classification Mistakes

Medical device manufacturers — particularly those entering the European market from other regulatory systems — make several recurring classification errors:

• Ignoring software classification (Rule 11): Companies that classified their software as Class I under the MDD discover it is now Class IIa or higher under EU MDR. This requires Notified Body involvement they had not planned for, delaying market access and invalidating tender compliance claims.

• Applying single rules when multiple apply: EU MDR states that when multiple rules apply to the same device, the highest classification takes precedence. A device that is Class IIa under Rule 9 but Class IIb under Rule 7 must be classified as Class IIb. Missing this hierarchy leads to under-classification and inadequate conformity assessment.

• Confusing intended purpose with actual use: Classification depends on the manufacturer's intended purpose, not how the device might be used. But if your intended purpose claims are narrower than how the device is typically used, post-market surveillance may reveal a classification discrepancy.

• Overlooking combination products: Devices that combine features from multiple rules — such as an active implantable device with drug delivery capability — require careful analysis under multiple rules simultaneously. The highest applicable class always governs.

How Classification Affects Tender Eligibility

Classification directly impacts tender response in several ways. First, tenders often specify required classification levels — a hospital may require Class IIb or higher for certain clinical applications. If your device is classified at a lower level, you may not be eligible to bid. Second, the conformity assessment pathway determines which certificates you can cite in your compliance evidence. A device classified as Class I self-declares conformity, while Class IIa and above require Notified Body certificates. Procurement authorities verify these certificates against the stated classification.

Orbid AI's Intel module maintains current EU MDR classification mappings and cross-references them against tender requirements. When building a tender response, Intel verifies that the device classification cited in the response matches the classification stated on the Notified Body certificate, matches the classification required by the tender, and aligns with the device's intended purpose claims. These verification steps, completed as part of Operator's 46-second parse-match-comply-draft pipeline, prevent classification-related disqualifications that manual processes frequently miss.

For Chinese medical device manufacturers expanding into Europe, classification under EU MDR is often the first major regulatory hurdle. Getting it right — and ensuring your tender responses accurately reflect your classification status — is the foundation of European market access. Contact Orbid AI to discuss how Intel maps your products' NMPA classifications to EU MDR equivalences.